Valneva SE
VALN Nasdaq· Biological Products, (No Diagnostic Substances)
KIRA · Stoqly’s AI analyst, in plain words
- Valneva SE had $197M of revenue in fiscal 2025, up 7.4% on the year before. Over five years, revenue changed +9.4% a year on average.
- Its operating margin was −47.0%, down 54.8 pts: of every 100 in sales, about −47 is left after running the business.
- Valneva SE lost $130M in fiscal 2025.
- Free cash flow was −$64.6M in fiscal 2025, −32.8% of revenue.
- Valneva SE owes $81.7M more than it holds in cash.
Market cap
—
P/E
—
Revenue
$197M
Net income
−$130M
Free cash flow
−$64.6M
Operating margin
−47.0%
Valneva SE in 30 seconds · fiscal 2025
Are sales growing?
+7.4%
Yes. Sales grew 7.4% last year.
Does it make a profit?
−66.0%
No. It lost money last year.
Does profit turn into cash?
−32.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
What Valneva SE does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 17, 2026
- Legal name
- Valneva SE
- CIK
- 0001836564
Valneva SE · VALN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $412M | $380M | $166M | $183M | $197M |
| Revenue growth | 227.4% | −7.8% | −56.2% | 10.4% | 7.4% |
| Gross margin | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| Operating margin | −17.6% | −31.4% | −53.4% | 7.9% | −47.0% |
| Net income | −$72.6M | −$151M | −$110M | −$13.2M | −$130M |
| Net margin | −17.6% | −39.7% | −66.0% | −7.2% | −66.0% |
| Diluted EPS | −$1.77 | −$2.61 | −$1.58 | −$0.17 | −$1.53 |
| Cash | |||||
| Cash from operations | $90.9M | −$258M | −$219M | −$72.7M | −$59.6M |
| Capital expenditure | $109M | $30.7M | $15.4M | $15.0M | $5.0M |
| Free cash flow | −$18.1M | −$289M | −$235M | −$87.7M | −$64.6M |
| FCF margin | −4.4% | −76.0% | −141.2% | −47.8% | −32.8% |
| Share count change | 7.6% | 18.3% | 20.0% | 5.1% | 15.4% |
| Debt and strength | |||||
| Cash and short-term investments | $393M | $306M | $139M | $175M | $129M |
| Debt incl. finance leases | $65.5M | $105M | $195M | $195M | $211M |
| Shareholders' equity | $193M | $234M | $142M | $188M | $125M |
| Net debt / EBITDA | — | — | — | 0.6x | — |
| Current ratio | 1.6x | 1.5x | 1.7x | 2.6x | 2.4x |
| Interest coverage | −3.6x | −6.0x | −3.5x | 0.6x | −2.0x |
| Returns and quality | |||||
| Return on capital | — | −275.4% | −35.5% | 5.5% | −35.4% |
| Return on equity | −50.4% | −70.4% | −58.3% | −8.0% | −83.0% |
| Return on tangible equity | −46.5% | −73.9% | −96.7% | −8.2% | −131.9% |
| Piotroski F-score | 5 | 1 | 3 | 5 | 2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Valneva SE · VALN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001836564). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.